Evidence map›Paper›PMID 36466554›Full record

ArticleComputational and mathematical methods in medicine2022

Research of the Active Components and Potential Mechanisms of Qingfei Gujin Decoction in the Treatment of Osteosarcoma Based on Network Pharmacology and Molecular Docking Technology.

Qingying Yan, Jiewen Yang, Yongwei Yao, Zhen Jia, Yiqing Wang, Miao Cheng, Xiaobo Yan, Yefeng Xu

Abstract read
In one paragraph

Article in Computational and mathematical methods in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qingying YanDepartment of Oncology, Hangzhou Third People's Hospital, Hangzhou, China.
Jiewen YangDepartment of Oncology, Hangzhou Third People's Hospital, Hangzhou, China.
Yongwei YaoDepartment of Oncology, Hangzhou Third People's Hospital, Hangzhou, China.
Zhen JiaDepartment of Oncology, Hangzhou Third People's Hospital, Hangzhou, China.
Yiqing WangDepartment of Oncology, Hangzhou Third People's Hospital, Hangzhou, China.
Miao ChengDepartment of Oncology, Hangzhou Third People's Hospital, Hangzhou, China.
Xiaobo YanDepartment of Orthopedics, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Yefeng XuDepartment of Oncology, Hangzhou Third People's Hospital, Hangzhou, China.ORCID https://orcid.org/0000-0002-6724-7492

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Qingfei Gujin Decoction (QGD) has been shown to be effective against osteosarcoma. This research was aimed at investigating the main active ingredients and potential mechanisms of QGD acting on osteosarcoma through network pharmacology and molecular docking techniques. Methods: The active ingredients and targets of QGD were screened from the TCMSP database, and the predicted targets were obtained from the PharmMapper database. Meanwhile, the targets of osteosarcoma were collected using OMIM, PharmGKB, and DisGeNET databases. Then, GO and KEGG enrichment analyses were performed by RStudio. PPI and drug-ingredient-target networks were constructed using Cytoscape 3.2.1 to screen the major active ingredients, key networks, and targets. Finally, molecular docking of key genes and their regulatory active ingredients was performed using AutoDockTools 1.5.6 software. Results: 38 active ingredients were collected, generating 89 cross-targets; quercetin, luteolin, Conclusion: QGD is effective against osteosarcoma through multicomponent, multitarget, and multipathway. This study was helpful for finding effective targets and compounds for osteosarcoma treatment.

Indexed as

Bone NeoplasmsOsteosarcomaHumansMolecular Docking SimulationNetwork PharmacologyPhosphatidylinositol 3-KinasesTechnologyPhosphatidylinositol 3-Kinases

Identifiers

PMID36466554
PMCPMC9713469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.